ReNerve Posts 79% Revenue Jump and Eyes Multiple Regulatory Wins in CY26

In its May 2026 quarterly webinar presentation, ReNerve Limited (ASX: RNV) outlined a period of strong commercial momentum, reporting 79% quarter-on-quarter revenue growth for Q3 FY26 (January to March 2026). The medical device company, which develops nerve repair and regeneration products, recorded $132,000 in quarterly sales and achieved its first $100,000+ revenue month in March 2026, with a cash position of $3.2M.

Breaking down the Q3 FY26 numbers

The Q3 FY26 result marked a meaningful step in ReNerve’s commercialisation trajectory. The presentation highlighted a consistent upward sales trend stretching from 2023 through to the current quarter, with the March 2026 milestone representing a significant threshold in the company’s revenue history.

Additional operational milestones highlighted in the presentation included:

• New regulatory approvals for the NervAlign® Nerve Cuff secured in Hong Kong and Malaysia
• Further progress toward NervAlign® Nerve Cuff approval in India
• NervAlign® Nerve Guide Matrix advancing to Stage 3 of Commercial Development
• 21 US distributors now active across the distribution network

What is nerve repair biomaterials? A primer for investors

Peripheral nerve damage, whether from trauma, surgery, or disease, can result in chronic pain, loss of sensation, or impaired motor function. Surgeons repairing these injuries require specialised devices to protect the nerve during the recovery process.

The NervAlign® Nerve Cuff addresses this need by wrapping around the repaired nerve post-surgery, providing a protective barrier while the tissue heals. The device is bio-absorbed within six months, removing the need for additional surgery to retrieve it.

The market opportunity is substantial. The Global Nerve Repair Biomaterials Market is projected to reach USD$6.19Bn by 2031, growing at a CAGR of 17.8% between 2024 and 2031. Adjacent markets targeted by ReNerve’s Empliq™ product range are also sizable, with surgical applications (trauma and plastic surgery) estimated at USD$1.90Bn and orthopaedics (tendon and ligament) at USD$1.10Bn by 2031.

The “Align” study and the pipeline fuelling future growth

Clinical validation: what the “Align” study shows

The Align study is a definitive clinical study examining the benefit of using the NervAlign® Nerve Cuff following nerve repair surgery. The study compares two patient cohorts: a control group receiving standard neurectomy repair, and a test group receiving neurectomy repair with the NervAlign® Nerve Cuff applied.

To date, 50 patients have been recruited, with recruitment targeting completion by mid-2026. Data publication and presentation is expected in late 2026 or early 2027. Early-stage supporting data from recruited patients to date shows a notable difference in post-surgical pain outcomes:

Key clinical data: early-stage pain score comparison

“Standard of care: post-surgery pain score 3.3 (54% improvement). NervAlign® Nerve Cuff protected: post-surgery pain score 0.4 (96% improvement).”

This data is preliminary and based on patients recruited so far, not a completed clinical outcome. Both cohorts entered surgery with a pre-surgery pain score of 7.1.

Pipeline: from nerve conduit to bionic nerve

Management outlined a staged product development pipeline extending through to 2028:

1. NervAlign® Nerve Conduit — targeting market release in CY26; significant scale manufacturing was underway during the quarter
2. NervAlign® Nerve Guide Matrix — currently in Stage 3 of 4 of commercial development; FDA approval pathway confirmed; targeting Q2 CY27 regulatory filing
3. NervAlign® Bionic Nerve — targeting Q3 CY28 FDA filing; designed for nerve replacement across lengths of 1cm to 20cm

The Empliq™ product range, comprising AmnioLite, AmnioDuo, Placental, and Dermal products, is already on market in the US, complementing NervAlign® nerve product sales across the existing distributor network.

Key catalysts to watch across CY26

The presentation outlined several catalysts management expects to progress during the remainder of CY26:

• NervAlign® Nerve Cuff approval in India, described as a major market opportunity
• European approval submission, utilising data from the Align study
• Additional approvals across South-East Asian jurisdictions
• Market launch of the first NervAlign® Nerve Conduit
• Continued NervAlign® Nerve Guide Matrix development toward its Q2 CY27 filing target
• Empliq™ brand growth in the US market
• Expansion of direct sales representative presence in the US to support the distributor network

With 21 US distributors active, regulatory approvals progressing across multiple international markets, and a pipeline spanning nerve conduit to bionic nerve technology, ReNerve is positioning itself to capture a growing share of the projected USD$6.19Bn global nerve repair biomaterials market.

Don’t Miss the Next Healthcare Breakout

Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ investors staying ahead of market-moving announcements before the rest of the market catches up. Click the “Free Alerts” button to start receiving alerts today.